32 results about "Gulose" patented technology

The present invention relates to an ophthalmic solution comprising 0.00001 to 10.0 weight percent of a simple saccharide, at least 0.00001 weight percent of a preservative, and not more than about 0.2 percent by weight chloride. The simple saccharide is chosen from the group consisting of: inositol; mannitol; sorbitol; sucrose; dextrose; glycerin; propylene glycol; ribose; triose; tetrose; erythrose; threose; pentose; arabinose; ribulose; xylose; xylulose; lyxose; hexose; allose; altrose; fructose; galactose; glucose; gulose; idose; mannose; sorbose; talose; tagatose; adlose; ketose; heptose; sedoheptulose; monosaccharides; disaccharides; sugar alcohols; xylitol; and polyol.

Disclosed is a preparation method of a bicyclol glycoside compound, which is characterized in that first bicyclol and glycine protected by Fmoc are condensed under the catalysis of 1-(3-dimethylamino propyl)-3-ethyl carbodiimide hydrochloride and 4-dimethylamino pyridine, and then protecting group of Fmoc is removed under the effect of acetonitrile diethylamine to obtain intermediate bicyclol-glycine ester which is the condensation of the bicyclol and the glycine. At last, Alpha or Beta glycosyl carboxyl methyl glycoside of glucose, galactose, mannose, allose, altrose, gulose, idose, talose, acetyl-glucosamine or acetyl galactosamine has condensation reaction with the intermediate bicyclol-glycine ester in solvent N-methyl pyrrolidone and under the effect of condensing agent and alkali. The water solubility of the bicyclol can be increased with the invention, and the bioavailability of the bicyclol is improved, which can provide enough raw material and effective compound route for the study of the anti-hepatitis drug. The invention has the advantages that the preparation method is simple and convenient; the condition is easy to control.

The invention provides a carbohydrate composition with a wound healing promoting effect and application of the carbohydrate composition. The carbohydrate composition contains at least five types of carbohydrate including carboxymethyl chitosan, rhizoma bletillae polysaccharides, fucoidan from fucus vesiculosus, heparan sulfate, chondroitin sulfate, oligosaccharides of hyaluronan and gulose aldehyde acid oligosaccharides. The carbohydrate composition and the application have the advantages that VEGFA (vascular endothelial growth factor A), FGF2 (fibroblast growth factor 2) and VE-cadherin protein mRNA (messenger ribonucleic acid) expression can be obviously improved by the carbohydrate composition, VEGF (vascular endothelial growth factor) secretion and skin fibroblast (HSF) and human immortalized keratinocyte (HaCaT) proliferation can be obviously promoted by the carbohydrate composition, and the obvious wound healing promoting effect can be realized by the carbohydrate composition; raw materials required by the carbohydrate composition are easily available, composition methods for the carbohydrate composition are simple, the carbohydrate composition is low in cost, easy to industrialize and wide in application range, and the like.

[PROBLEMS] To find out a specific rare sugar having effects of inhibiting the proliferation of vascular endothelial cells and lumen formation and utilize these effects. To provide this rare sugar as a preventive / remedy for diseases with angiogenesis, a cosmetic or a functional food.[MEANS FOR SOLVING PROBLEMS] A method of controlling the proliferation of vascular endothelial cells characterized by utilizing the vascular endothelial cell proliferation-controlling effect of D-mannose, D-allose, 2-deoxy-D-glucose, 3-deoxy-D-glucose, L-sorbose, 2-deoxy-D-ribose and / or 2-deoxy-L-ribose. A method of inhibiting lumen formation of vascular endothelial cells characterized by utilizing the vascular endothelial cell lumen formation-inhibiting effect of D-allose, D-altrose, D-gulose, D-talose, L-allose, 2-deoxy-D-glucose, 3-deoxy-D-glucose, D-ribose, L-ribose, 2-deoxy-D-ribose and / or 2-deoxy-L-ribose.

The invention relates to the medicine technology field, in particular relates to a new application of cardiac glycoside chemical compound having general formula (I) in preparing oncotherapy drug, wherein, R equals to 2-O-methyl-Beta-D-mycose, 6-deoxidation-Beta-D-gulose or 6-deoxidation-2-O-methyl-Beta-D-allose. The cardiac glycoside chemical compound can be obtained through a separation from upas in various conventional separation methods or be obtained through a synthesis or semisynthesis method.

A chewing gum base comprises food acceptable substituted polysaccharides wherein substituents on the saccharide units in the polysaccharides produce a degree of substitution of at least I.0. The polysaccharides may have branches with an average length of 1 to 15 saccharide units per branch. The polysaccharides may be linked saccharide units such as allose, altrose, mannose, gulose, idose, galactose, 3,6 anhydro galactose, glucuronic acid, mannuronic acid, galacturonic acid, aldobiouronic acid, fucose, rhamnose, arabinose, xylose, talose, acyl substituted glucose, fructose, lactose and combinations thereof.

The invention discloses a BCL-2 selective inhibitor with a sugar ring structure and application of the BCL-2 selective inhibitor in medicine for treating diseases like tumors, immune and autoimmune diseases, and the like, caused by BCL-2 overexpression. The BCL-2 selective inhibitor is characterized in that a sugar ring is monosaccharide and alkyl, thioether or alkenyl derivatives thereof, or oligosaccharide and alkyl, thioether or alkenyl derivatives thereof; monosaccharide is selected from glucose, mannose, galactose, fructose, xylose, arabinose, ribose, desoxyribose, allose, altrose, gulose, idose, talose or threose; and oligosaccharide is selected from saccharose, maltose, cellobiose, lactose or raffinose.

The invention discloses a glucose group-terminated PLLA diblock copolymer material and a preparation method thereof, belonging to the technical field of high polymer materials. The preparation methodcomprises the following steps: firstly, subjecting PLLA and 1,2:5,6-di-O-isopropylidene-D-gulose (IPG) serving as raw materials to a reaction under the conditions that a molar ratio of IPG to PLLA isgreater than 4: 1, a polymerization pressure is 10-300 Pa, and a polymerization temperature is 160-200 DEG C; and carrying out a melt polymerization reaction for 4-12 hours to prepare a poly(L-lacticacid)-isopropylidene glucose diblock copolymer (PLLAIPG), and removing a hydroxyl protection group of the PLLAIPG to obtain the glucose group-terminated PLLA diblock copolymer (PLLAG). The PLLAG material has a melting temperature of about 150 DEG C and a crystallinity of about 50%, which are similar to those of PLLA, but the hydrophilicity of the PLLAG material is superior to the hydrophilicity ofPLLA; and the contact angle of the PLLAG material is about 65 degrees while the contact angle of PLLAG is 88 degrees.

It is intended to provide a radioactive diagnostic imaging agent comprising a radioactive halogen-labeled compound as an active ingredient, in which the active ingredient is prevented from radiolysis and its stability is improved. This is achieved by adding a biologically-acceptable sugar or sugar alcohol to the radioactive diagnostic imaging agent in an amount effective to prevent radiolysis. The amount of the sugar or sugar alcohol to be added is preferably 10 (mmol / L) / GBq / mL or more, and more preferably 50 (mmol / L) / GBq / mL or more. The sugar is preferably selected from the group consisting of erythrose, threose, ribose, arabinose, xylose, lyxose, allose, altrose, glucose, mannose, gulose, idose, galactose, talose, erythrulose, ribulose, xylulose, psicose, fructose, sorbose, and tagatose. The sugar alcohol is preferably selected from the group consisting of erythritol, xylitol, sorbitol, and mannitol.

Novel compounds, called liamocins from Aureobasidium pullulans, having the general structure in Formula 1 are disclosed.where R1 is either COCH3 or H; and R2 is between two to ten O-linked 3,5-dihydroxydecanoate; and R3 can be a polyol (e.g., L- or D-glycerol, L- or D-threitol, L- or D-erythritol, L- or D-arabitol, L- or D-xylitol, L- or D-lyxitol, L- or D-ribitol, L- or D-allitol, L- or D-altritol, L- or D-mannitol, L- or D-iditol, L- or D-gulitol, L- or D-glucitol (also called sorbitol), L- or D-galactitol (also called dulcitol), and L- or D-talitol), 2-amino-D-mannitol, 2N-acetylamino-D-mannitol, L-rhamnitol, or D-fucitol; except when R3 is D-mannitol, R2 is not 2 nor 3 O-linked 3,5-dihydroxydecanoate chains. These liamocins described above in addition to D-mannitol liamocin A1, D-mannitol liamocin A2, D-mannitol liamocin B1, and D-mannitol liamocin B2, alone or in combination with each other, can be used to kill certain bacteria and to treat certain bacterial infections.

A composition comprising at least two glycoalkaloids of formula I: wherein: either one or both of the dotted lines represents a double bond, and the other a single bond, or both represent single bonds; A: represents a radical selected from the following radicals of general formulae (II) to (V): each of R1 is a radical separately selected from the group consisting of hydrogen, amino, oxo and OR4; each of R2 is a radical separately selected from the group consisting of hydrogen, amino and OR4; each of R3 is a radical separately selected from the group consisting of hydrogen, carbohydrate and a carbohydrate derivative; “X” is a radical selected from the group comprising —CH2—, —O— and —NH2—; and wherein the compound includes at least one R4 group that is a carbohydrate or a derivative thereof selected from the group comprising glyceric aldehyde, glycerose, erythrose, threose, ribose, arabinose, xylose, lyxose, altrose, allose, gulose, mannose, glucose, idose, galactose, talose, rhamnose, dihydroxyactone, erythrulose, ribulose, xylulose, psicose, fructose, sorbose, tagatose, and other hexoses, heptoses, octoses, nanoses, decoses, deoxysugars with branched chains, (e.g. apiose, hamamelose, streptose, cordycepose, mycarose and cladinose), compounds wherein the aldehyde, ketone or hydroxyl groups have been substituted (e.g. N-acetyl, acetyl, methyl, replacement of CH2OH), sugar alcohols, sugar acids, benzimidazoles, the enol salts of the carbohydrates, saccharinic acids, sugar phosphates; wherein the ratio of said glycoalkaloids is between 6:1 and 1:6 and on the proviso that when the glycoalkaloids are solamargine and solasonine and they are present in a 1:1 ratio the solamargine and solasonine are isolated.

Herein is disclosed a method of generating ascorbic acid from yeast. In one embodiment, the yeast is a Zygosaccharomyces spp. or a Kluyveromyces spp. growing in a medium comprising an ascorbic acid precursor. In a second embodiment the yeast is a recombinant yeast growing in a medium comprising an ascorbic acid precursor. Preferably the recombinant yeast is transformed with a coding region encoding an enzyme selected from L-galactose dehydrogenase (LGDH), L-galactono-1,4-lactone dehydrogenase (AGD), D-arabinose dehydrogenase (ARA), D-arabinono-1,4-lactone oxidase (ALO) or L-gulono-1,4-lactone oxidase (RGLO). The ascorbic acid precursor is preferably D-glucose, L-galactose, L-galactono-1,4-lactone, or L-gulono-1,4-lactone. In another preferred embodiment the ascorbic acid is accumulated in the medium at levels greater than background. Preferably, the yield of the conversion of the precursor to ascorbic acid is preferably at least about 35%.

L-gulose is a rare aldohexose, which can be used as a synthetic precursor of vitamin C and a drug intermediate for the synthesis of nucleoside antiviral drugs, with high potential economic value. In view of the shortcomings of the existing gulose synthesis process, the present invention co-expressed NAD+-dependent mannitol dehydrogenase and NADH oxidase in Escherichia coli to construct a whole-cell biocatalyst. A green biosynthetic process for the preparation of L-gulose.

The invention provides a beta-elemene substituted ethyl peracetylated sugar complex, a beta-elemene substituted ethyl sugar complex, and preparation methods and use. The beta-elemene substituted ethyl peracetylated sugar complex has a structure in a general formula I, wherein the complex is peracetylated galactose, peracetylated fucose, peracetylated rhamnose, peracetylated gulose, peracetylated lactose or peracetylated maltose when X is S or Se; and the complex is peracetylated glucose, peracetylated mannose, peracetylated galactose, peracetylated fucose, peracetylated rhamnose, peracetylated gulose, peracetylated lactose or peracetylated maltose when X is O or NH. The water-solubility is enhanced by leading in a polar ground to a beta-elemene structure; the beta-elemene substituted ethyl peracetylated sugar complex has important significance on research and application of the beta-elemene in the field of a medicine.

The invention discloses gulose tablet excipient, which consists of the following ingredients in percentage by weight: 88 percent to 96 percent of gulose, 1 percent to 5 percent of starch octenyl succinate anhydride, 1 percent to 5 percent of silicon dioxide and 1 percent to 5 percent of porcellanite, and has the advantages that the mobility is good, the forming degree is good, the demolding performance is good, and the gulose tablet excipient can be directly tableted with medicine and water for preparing medicine tablets. The invention also discloses a medicine tablet, which is prepared from the following ingredients in percentage by weight: 75 percent to 85 percent of medicine active ingredients, 5 percent to 15 percent of gulose tablet excipient and 5 percent to 15 percent of water raw materials, wherein the gulose tablet excipient and the medicine active ingredients do not have incompatibility and reaction, in addition, the solvability is good, the flowability is good, and the medicine tablet is suitable for the direct tableting of various kinds of medicine. The invention also discloses a preparation method of the medicine tablet, which has the advantages that the preparation is simple, the implementation is easy, and the operation and the control are easy.

The present invention discloses a process for producing sodium 2-keto-L-gulonate from sorbitol and recovering 2-keto-L-gulonic acid in high recovery yields, by controlled cation exchange treatment of the micro-organism free fermentation broth and / or adjusting Ph of said purified fermentation broth, followed by direct crystallization of 2-keto-L-gulonic acid monohydrate.

The invention relates to the medicine technology field, in particular relates to a new application of cardiac glycoside chemical compound having general formula (I) in preparing oncotherapy drug, wherein, R equals to 2-O-methyl-Beta-D-mycose, 6-deoxidation-Beta-D-gulose or 6-deoxidation-2-O-methyl-Beta-D-allose. The cardiac glycoside chemical compound can be obtained through a separation from upasin various conventional separation methods or be obtained through a synthesis or semisynthesis method.

The invention relates to immobilized enzyme compositions for the preparation of a hexose. Hexoses include, for example, tagatose, psicose, fructose, allose, mannose, galactose, altrose, talose, sorbose, gulose, idose, and inositol. The invention also relates to an enzymatic process for preparing a hexose from a saccharide by contacting a starch derivative with an immobilized enzyme composition of the invention.

The present invention provides a process for the production of vitamin C from different substrates like D-sorbitol, L-sorbose, L-sorbosone or L-gulose using a microorganism selected from the group consisting of Gluconobacter oxydans DSM 4025 (FERM BP-3812), a microorganism belonging to the genus Gluconobacter and having identifying characteristics of G. oxydans DSM 4025 (FERM BP-3812) and mutants thereof.